Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Rashmi Kanagal-Shamanna, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Nicholas J. Short, MD, C. Cameron Yin, MD PhD, Keyur Patel, MD PhD, Sanam Loghavi, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Susan M. O'Brien, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-142012

Published: 2020

Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141411

Published: 2020

Journal Articles

High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Rajyalakshmi Luthra, PhD, Hui Yang, PhDMD, Gokce A. Toruner, MD PhD, Keyur P. Patel, MBBS, PhD, Saradhi Mallampati, DVM, PhD, Hagop M. Kantarjian, MD, Carlos E. Bueso-Ramos, MD PhD, L. Jeffrey Medeiros, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 5438.

https://doi.org/10.1182/blood-2019-131971

Published: 2019

Journal Articles

Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL

Preetesh Jain, MBBS,MDDM,PhD, Jan A. Burger, MD PhD, Graciela Nogueras González, Rashmi Kanagal-Shamanna, MD, Uri Rozovski, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, William G Wierda, MD PhD, Philip A Thompson, MBBS, Nawid Sarwari, MD, Rajyalakshmi Luthra, PhD, Andrew Quesada, Nitin Jain, MD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 3006.

https://doi.org/10.1182/blood.V130.Suppl_1.3006.3006

Published: 2017

Journal Articles

Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care

Chi Young Ok, MD, Rajesh Singh, PhD, Rajyalakshmi Luthra, PhD, David Hatfield, Kristen Floyd, Sanam Loghavi, MD, Rashmi Kanagal-Shamanna, MD, Zhuang Zuo, C. Cameron Yin, MD PhD, Mark Routbort, MD PhD, Hagop M. Kantarjian, MD, L. Jeffrey Medeiros, MD, Keyur P. Patel, MBBS, PhD

Blood (2017) 130 (Supplement 1): 2679.

https://doi.org/10.1182/blood.V130.Suppl_1.2679.2679

Published: 2017

Journal Articles

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Rajyalakshmi Luthra, PhD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Farhad Ravandi, MBBS, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2727.

https://doi.org/10.1182/blood.V122.21.2727.2727

Published: 2013

Journal Articles

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Joyce Bass, Mark Brandt, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 3971.

https://doi.org/10.1182/blood.V122.21.3971.3971

Published: 2013

Journal Articles

Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia

Lorenzo Falchi, MD, Hagop M. Kantarjian, MD, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Elias J. Jabbour, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Rajyalakshmi Luthra, PhD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 164.

https://doi.org/10.1182/blood.V120.21.164.164

Published: 2012

Journal Articles

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Cecilia Y Arana Yi, MD, Jorge Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Zeev Estrov, MD, PhD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Mark J. Levis, MD, PhD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Keith W. Pratz, MD, Rajyalakshmi Luthra, PhD, Michael Andreeff, MD, PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 1516.

https://doi.org/10.1182/blood.V120.21.1516.1516

Published: 2012

Journal Articles

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Aziz Nazha, Hagop M. Kantarjian, MD, Preetesh Jain, MD, DM, PhD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, M.D., Rajyalakshmi Luthra, PhD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3757.

https://doi.org/10.1182/blood.V120.21.3757.3757

Published: 2012

Journal Articles

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Keyur P. Patel, MD, PhD, Guillermo Garcia Manero, Ohad Benjamini, MD, Gautam Borthakur, M.D., Naveen Pemmaraju, M.D., Tapan M. Kadia, M.D., Naval G. Daver, MD, Aziz Nazha, Rajyalakshmi Luthra, PhD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2484.

https://doi.org/10.1182/blood.V120.21.2484.2484

Published: 2012

Journal Articles

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Elias J. Jabbour, MD, Naval Daver, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Alfonso Quintás-Cardama, MD, Rajyalakshmi Luthra, PhD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2623.

https://doi.org/10.1182/blood.V120.21.2623.2623

Published: 2012

Journal Articles

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, Rajyalakshmi Luthra, PhD, Susan O'Brien, MD, Elias Jabbour, Alfonso Quintas-Cardama, MD, Gautam Borthakur, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Elizabeth Burton, Brenda Walker, RN, Jorge E. Cortes

Blood (2011) 118 (21): 1700.

https://doi.org/10.1182/blood.V118.21.1700.1700

Published: 2011

Journal Articles

FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations

Yesid Alvarado, MD, Hagop M. Kantarjian, Farhad Ravandi, MD, Rajyalakshmi Luthra, PhD, Gautam Borthakur, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Marina Konopleva, MD, PhD, Zeev Estrov, Michael Andreeff, M.D., Ph.D., Jorge E. Cortes

Blood (2011) 118 (21): 1493.

https://doi.org/10.1182/blood.V118.21.1493.1493

Published: 2011

Journal Articles

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Farhad Ravandi, MD, Deborah A. Thomas, MD, Susan O'Brien, MD, Rebecca Garris, BSc, Stefan Faderl, MD, Jianqin Shan, PhD, Gautam Borthakur, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Partow Kebriaei, MD, Richard Champlin, MD, Zeev Estrov, Sa A. Wang, MD, Jeffrey L. Jorgensen, MD, PhD, Rajyalakshmi Luthra, PhD, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2011) 118 (21): 1453.

https://doi.org/10.1182/blood.V118.21.1453.1453

Published: 2011

Journal Articles

TP53 Mutation Is Rare In Primary Myelofibrosis

Wesley O. Greaves, MD, Shalini Verma, MD, Tigist Bisrat, Hamed Rahimi, Abhaya Paladugu, Carlos E. Bueso-Ramos, MD, PhD, Keyur P. Patel, MD, PhD, Rajyalakshmi Luthra, PhD, Hui Yao, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 5241.

https://doi.org/10.1182/blood.V118.21.5241.5241

Published: 2011

Journal Articles

Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP),

Kiran Naqvi, MD, Hagop M Kantarjian, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, Susan O'Brien, MD, Elizabeth M Burton, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, William G. Wierda, MD, PhD, Gautam Borthakur, Alfonso Quintas-Cardama, MD, Jorge E. Cortes

Blood (2011) 118 (21): 3784.

https://doi.org/10.1182/blood.V118.21.3784.3784

Published: 2011

Journal Articles

Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,

Aziz Nazha, Jorge E. Cortes, Stefan Faderl, MD, Sherry Pierce, RN, BS, Guillermo Garcia-Manero, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Tapan Kadia, Gautam Borthakur, Rajyalakshmi Luthra, PhD, Hagop M. Kantarjian, Farhad Ravandi, MD

Blood (2011) 118 (21): 3557.

https://doi.org/10.1182/blood.V118.21.3557.3557

Published: 2011

Journal Articles

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

Alfonso Quintás-Cardama, MD, Hagop M Kantarjian, Rajyalakshmi Luthra, PhD, Susan o'Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, Stefan Faderl, MD, Marina Konopleva, M.D., Ph.D., William G. Wierda, MD, PhD, Elizabeth Burton, Jorge E. Cortes

Blood (2011) 118 (21): 454.

https://doi.org/10.1182/blood.V118.21.454.454

Published: 2011

Journal Articles

Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant

Gautam Borthakur, MD, Amer Beitinjaneh, MD, E. Lin, Jorge E. Cortes, MD, Rajyalakshmi Luthra, PhD, Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Akhshar Hemantkumar Patel, Gabriela Rondon, MD, Sergio Giralt, MD, Richard Champlin, Hagop Kantarjian, MD, Marcos de Lima, MD

Blood (2010) 116 (21): 1722.

https://doi.org/10.1182/blood.V116.21.1722.1722

Published: 2010

NARROW

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes

Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL

Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

TP53 Mutation Is Rare In Primary Myelofibrosis

Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP),

Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only